Pharmaceutical Contract Manufacturing & Contract Research Market By Services (CMO {API/Bulk Drugs, Advanced Drug Delivery Finished Dose Formulations}, CRO {Oncology, Vaccines, Immunology Cardiology, Neuroscience}), & Segment Forecasts, 2014 - 2025

The global pharmaceutical contract manufacturing/contract research market is anticipated to reach USD 238.3 billion by 2025, according to a new report by Grand View Research, Inc. Impact on the volume of capacity that is required for production due to of increasing expression levels is anticipated to influence outsourcing industry. Increased cell densities as well as increase in expression of each cell has led to the steady decline in the volume requirement. The aforementioned fact provides the client with choices for in selection from several CMOs, which was not the fact earlier.
The focus of large pharmaceutical companies to strategically engage with a small number of preferred providers is a meaningful departure from the procurement-based outsourcing. This was one of the many approaches that the service industry had become accustomed to.
Expanding market for biosimilars and biobetters is anticipated to pronounce the demand for contract development and manufacturing support. Service providers that hold the potential of providing cost as well as quality advantages are set to make inroads and grow at tremendous pace in the forecast period.
However, as drug manufacturers are increasing the investments with respect to production capabilities. This may limit the potential growth of contract manufacturing services to traditional customers thereby hampering industrial growth.
Further Key Findings from the Report Suggest:
‧ Contract manufacturing services estimated to dominate the market over research services
‧ These services are segmented on the basis of development of different forms of formulations. Active Pharmaceutical Ingredient (API) / Bulk drugs registered the largest share of revenue.
‧ Pharmaceutical companies prefer the outsourcing services for API research and manufacture
‧ Factors supportive for this trend includes reduction in the cost of production of APIs
‧ Active molecules from small companies are always acquired by the big pharmaceutical companies
‧ The prominent entities focus on marketing rather than core competencies of production of API in order to maintain presence
‧ Finished dose formulations are expected to register the fastest growth in the coming years
‧ Contract research services for oncology dominated the market and are anticipated to maintain the dominance in the coming years
‧ CMOs/CDMOs with the ability to establish facilities in emerging countries are expected to drive growth
‧ Companies can position themselves for strong growth, given that demand is expected to expand rapidly in the coming years
‧ The major countries include Brazil. Russia, India, and China as the contract service sector is in its infancy in these regions
‧ Key players contributing in this market are AbbVie Contract Manufacturing, Catalent, Grifols International, S.A., Baxter BioPharma Solutions, Boehringer Ingelheim Biopharmaceuticals Gmbh, Dalton Pharma Services, and Patheon.
‧ Companies are engaged in lifecycle management of small-molecule drugs through the development of modified generics with uniquely enhanced properties
‧ Increased competitiveness in the contract service sector is anticipated to ultimately benefit the sector growth

Table of Contents
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Pharmaceutical Contract Manufacturing/Contract Research Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Drug shortage leading to drive demand for pharmaceutical development
3.1.1.2 Commercial success of biologics for clinical use
3.1.1.3 Lower manufacturing costs and improving economic condition of BRIC
3.1.2 Market restraint analysis
3.1.2.1 Limited outsourcing among big pharma companies’ clients
3.1.2.2 Regulatory issues pertaining to the drug approval
3.2 Penetration &Growth Prospect Mapping, 2016
3.3 Pharmaceutical Contract Manufacturing & Research Services - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Pharmaceutical Contract Manufacturing/Contract Research Market Categorization: Service Estimates & Trend Analysis
4.1 Pharmaceutical contract manufacturing & research servicesmarket: Service movement analysis
4.2 Manufacturing
4.2.1 Contract manufacturing services market, 2014 - 2025 (USD Billion)
4.2.2 API/bulk drugs
4.2.2.1 API/bulk drugs contract manufacturing market, 2014 - 2025 (USD Billion)
4.2.3 Advanced drug delivery formulations contract manufacturing
4.2.3.1 Advanced drug delivery formulations contract manufacturing services market, 2014 - 2025 (USD Billion)
4.2.4 Packaging
4.2.4.1 Packaging contract services market, 2014 - 2025 (USD Billion)
4.2.5 Finished dose formulations contract manufacturing
4.2.5.1 Finished dose formulations contract manufacturing market, 2014 - 2025 (USD Billion)
4.2.5.2 Solid finished dose formulations contract manufacturing
4.2.5.2.1 Solid finished dose formulations contract manufacturing market, 2014 - 2025 (USD Billion)
4.2.5.3 Liquid formulations
4.2.5.3.1 Liquid formulations contract manufacturing market, 2014 - 2025 (USD Billion)
4.2.5.4 Semi-solid formulations contract manufacturing
4.2.5.4.1 Semi-solid formulations contract manufacturing market, 2014 - 2025 (USD Billion)
4.3 Research
4.3.1 Research services market, 2014 - 2025 (USD Billion)
4.3.2 Oncology
4.3.2.1 Oncology market, 2014 - 2025 (USD Billion)
4.3.3 Vaccines
4.3.3.1 Vaccines market, 2014 - 2025 (USD Billion)
4.3.4 Inflammation & immunology
4.3.4.1 Inflammation & immunology market, 2014 - 2025 (USD Billion)
4.3.5 Cardiology
4.3.5.1 Cardiology market, 2014 - 2025 (USD Billion)
4.3.6 Neuroscience
4.3.6.1 Neuroscience market, 2014 - 2025 (USD Billion)
4.3.7 Other
4.3.7.1 Other research services market, 2014 - 2025 (USD Billion)
Chapter 5 Pharmaceutical Contract Manufacturing/Contract Research Market Categorization: Country Estimates & Trend Analysis, by Service
5.1 Global Pharmaceutical Contract Manufacturing/Contract Research Market Share By Country, 2016& 2025
5.2 North America
5.2.1 North America pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.2.2 U.S.
5.2.2.1 U.S. pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.2.3 Canada
5.2.3.1 Canada pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.3 Europe
5.3.1 Europe pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.3.2 Germany
5.3.2.1 Germany pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.3.3 UK
5.3.3.1 UK pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.4 Asia Pacific
5.4.1 Asia Pacific pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.4.2 India
5.4.2.1 India pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.4.3 China
5.4.3.1 China pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.5 Latin America
5.5.1 Latin America pharmaceutical contract manufacturing market, 2014 - 2025 (USD Billion)
5.5.2 Brazil
5.5.2.1 Brazil pharmaceutical contract manufacturing market, 2014 - 2025 (USD Billion)
5.5.3 Mexico
5.5.3.1 Mexico pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.5.4 Colombia
5.5.4.1 Colombia pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.5.5 Argentina
5.5.5.1 Argentina pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.5.6 Chile
5.5.6.1 Chile pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.5.7 Venezuela
5.5.7.1 Venezuela pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.6 MEA
5.6.1 MEA pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
5.6.2 South Africa
5.6.2.1 South Africa pharmaceutical contract manufacturing & research services market, 2014 - 2025 (USD Billion)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Market Participation Categorization
6.3 Company Profiles
6.3.1 Boehringer Ingelheim GmbH
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Product benchmarking
6.3.1.4 Strategic initiatives
6.3.2 Lonza
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Product benchmarking
6.3.2.4 Strategic initiatives
6.3.3 Grifols S.A
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Product benchmarking
6.3.3.4 Strategic initiatives
6.3.4 Jubilant Life Sciences Limited
6.3.4.1 Company overview
6.3.4.2 Financial Performance
6.3.4.3 Product benchmarking
6.3.4.4 Strategic initiatives
6.3.5 Pfizer, Inc. (Pfizer CenterOne)
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 Charles River Laboratories International, Inc.
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Product benchmarking
6.3.6.4 Strategic initiatives
6.3.7 Albany Molecular Research, Inc.
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 Product benchmarking
6.3.7.4 Strategic initiatives
6.3.8 Covance, Inc. (LabCorp)
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 Product benchmarking
6.3.8.4 Strategic initiatives
6.3.9 QuintilesIMS
6.3.9.1 Company overview
6.3.9.2 Financial performance
6.3.9.3 Product benchmarking
6.3.9.4 Strategic initiatives
6.3.10 Baxter BioPharma Solutions
6.3.10.1 Company overview
6.3.10.2 Financial performance
6.3.10.3 Product benchmarking
6.3.10.4 Strategic initiatives
6.3.11 Aenova Holding GmbH
6.3.11.1 Company Overview
6.3.11.2 Financial performance
6.3.11.3 Product benchmarking
6.3.11.4 Strategic initiatives
6.3.12 Vetter Pharma
6.3.12.1 Company Overview
6.3.12.2 Financial performance
6.3.12.3 Product benchmarking
6.3.12.4 Strategic initiatives
6.3.13 Valeant Pharmaceuticals International Inc.
6.3.13.1 Company Overview
6.3.13.2 Financial performance
6.3.13.3 Product benchmarking
6.3.14 Ligand Pharmaceuticals, Inc.
6.3.14.1 Company Overview
6.3.14.2 Financial performance
6.3.14.3 Product benchmarking
6.3.14.4 Strategic initiatives
6.3.15 Pharmaceutical Product Development, LLC
6.3.15.1 Company Overview
6.3.15.2 Financial performance
6.3.15.3 Product benchmarking
6.3.15.4 Strategic initiatives
6.3.16 Recipharm AB.
6.3.16.1 Company Overview
6.3.16.2 Financial performance
6.3.16.3 Product benchmarking
6.3.16.4 Strategic initiatives
6.3.17 AbbVie, Inc.
6.3.17.1 Company Overview
6.3.17.2 Financial performance
6.3.17.3 Product benchmarking
6.3.17.4 Strategic initiatives
6.3.18 Famar Health Care Services
6.3.18.1 Company Overview
6.3.18.2 Financial performance
6.3.18.3 Product benchmarking
6.3.18.4 Strategic initiatives
6.3.19 Catalent Pharma Solutions
6.3.19.1 Company Overview
6.3.19.2 Financial performance
6.3.19.3 Product benchmarking
6.3.19.4 Strategic initiatives
6.3.20 West Pharmaceutical Services, Inc.
6.3.20.1 Company Overview
6.3.20.2 Financial performance
6.3.20.3 Product benchmarking
6.3.20.4 Strategic initiatives